After the close, DepoMed Inc. (NASDAQ: DEPO) reported Q1 EPS of $1.77, $0.72 better than the analyst estimate of $1.05. Revenue for the quarter came in at $83.1 million versus the consensus estimate of $81.42 million.

Earnings